Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07137598 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

A Phase 2 study of Rheumatoid Arthritis, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 2
Development phase
160
Enrollment target
20
Study locations

NCT07137598 is a Phase 2 study of Rheumatoid Arthritis that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 160 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07137598, a Phase 2 study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 2
Development phase
160 participants
Enrollment target
20
Study locations

Study Summary

This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Placebo
  • DRUG Afimkibart

Study Locations (20)

Other

  • UZ Leuven - Leuven
  • Bispebjerg og Frederiksberg Hospital - Frederiksberg
  • Nzoz Bif-Med - Bytom
  • Centrum Kliniczno-Badawcze J. Brzezicki, B. Górnikiewicz-Brzezicka Lekarze Spó?ka Partne - Elbl?g
  • Malopolskie Badania Kliniczne - Krakow
  • Zespol Poradni Specjalistycznych REUMED - Lublin
  • Twoja Przychodnia NCM - Nowa Sól

Texas

  • Accurate Clinical Management - Houston
  • DM Clinical Research - Tomball

Arizona

  • SunValley Arthritis Center Ltd. - Peoria

California

  • Inland Rheumatology Clinical Trials Incorporated - Upland

Florida

  • West Broward Rheumatology Associates, Inc. - Tamarac

Illinois

  • Willow Rheumatology and Wellness PLLC - Willowbrook

Louisiana

  • Accurate Clinical Research Inc. - Lake Charles

Pennsylvania

  • Altoona Center For Clinical Research - Duncansville

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2025-12-05
Est. Completion 2027-10-02
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07137598

The ClinicalTrials.gov registry entry for NCT07137598 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07137598 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT07137598 about?

NCT07137598 is a clinical study titled "A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)". This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.

What is the current status of trial NCT07137598?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-12-05. Estimated completion is 2027-10-02.

What conditions does trial NCT07137598 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT07137598?

The interventions under investigation include: Placebo (DRUG), Afimkibart (DRUG).

Who is sponsoring clinical trial NCT07137598?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07137598 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.